NCT02040415View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Conditions
Acute Back Pain
Interventions
DRUG

DW-1030(eperisone HCl) 75mg

DRUG

Myonal Tab.(eperisone HCl) 50mg

DRUG

Placebo drug of DW-1030

DRUG

Placebo drug of Myonal Tab.

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY